TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05095207: Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Sponsor: Icahn School of Medicine at Mount Sinai · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$9,149,910

Rescue Site Savings

+$6,047,580

Unlock Full NCT05095207 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05095207 Rescue Dossier →